GT201500025A - Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa - Google Patents

Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa

Info

Publication number
GT201500025A
GT201500025A GT201500025A GT201500025A GT201500025A GT 201500025 A GT201500025 A GT 201500025A GT 201500025 A GT201500025 A GT 201500025A GT 201500025 A GT201500025 A GT 201500025A GT 201500025 A GT201500025 A GT 201500025A
Authority
GT
Guatemala
Prior art keywords
inhibitor
optionally
pi3k
alfa
egfr
Prior art date
Application number
GT201500025A
Other languages
English (en)
Spanish (es)
Inventor
Giordano Caponigro
Darrin Stuart
Parseval Laure Moutouh-De
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48980368&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201500025(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of GT201500025A publication Critical patent/GT201500025A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GT201500025A 2012-08-07 2015-02-06 Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa GT201500025A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261680473P 2012-08-07 2012-08-07

Publications (1)

Publication Number Publication Date
GT201500025A true GT201500025A (es) 2017-09-28

Family

ID=48980368

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201500025A GT201500025A (es) 2012-08-07 2015-02-06 Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa

Country Status (39)

Country Link
US (1) US9474754B2 (OSRAM)
EP (2) EP2882440B1 (OSRAM)
JP (3) JP6342396B2 (OSRAM)
KR (1) KR102112885B1 (OSRAM)
CN (1) CN104519887B (OSRAM)
AR (1) AR092045A1 (OSRAM)
AU (1) AU2013299841B8 (OSRAM)
CA (1) CA2879548C (OSRAM)
CL (1) CL2015000294A1 (OSRAM)
CO (1) CO7200273A2 (OSRAM)
CY (1) CY1122143T1 (OSRAM)
DK (1) DK2882440T3 (OSRAM)
EA (1) EA028420B1 (OSRAM)
EC (1) ECSP15008695A (OSRAM)
ES (1) ES2717911T3 (OSRAM)
GT (1) GT201500025A (OSRAM)
HK (1) HK1211831A1 (OSRAM)
HR (1) HRP20190537T1 (OSRAM)
HU (1) HUE042877T2 (OSRAM)
IL (1) IL236934B (OSRAM)
IN (1) IN2015DN00450A (OSRAM)
JO (1) JOP20130236B1 (OSRAM)
LT (1) LT2882440T (OSRAM)
MA (1) MA37829A1 (OSRAM)
MX (1) MX359403B (OSRAM)
MY (1) MY176031A (OSRAM)
NZ (1) NZ703940A (OSRAM)
PE (2) PE20191655A1 (OSRAM)
PH (1) PH12015500246A1 (OSRAM)
PL (1) PL2882440T3 (OSRAM)
PT (1) PT2882440T (OSRAM)
RS (1) RS58734B1 (OSRAM)
SG (1) SG11201500321YA (OSRAM)
SI (1) SI2882440T1 (OSRAM)
TN (1) TN2015000027A1 (OSRAM)
TR (1) TR201904980T4 (OSRAM)
TW (1) TWI607754B (OSRAM)
UA (1) UA115786C2 (OSRAM)
WO (1) WO2014025688A1 (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014025688A1 (en) * 2012-08-07 2014-02-13 Novartis Ag Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
SI2976106T1 (sl) 2013-03-21 2021-08-31 Array Biopharma Inc. Kombinacijska terapija, ki vsebuje zaviralec B-Raf in drugi zaviralec
WO2015145388A2 (en) * 2014-03-27 2015-10-01 Novartis Ag Methods of treating colorectal cancers harboring upstream wnt pathway mutations
CN106574297B (zh) * 2014-06-16 2020-07-21 环球创新网络公司 选择用于癌症治疗的个体化三联疗法的方法
WO2016193955A1 (en) * 2015-06-04 2016-12-08 Giorgio Stassi Combinations of kinase inhibitors for treating colorectal cancer
EP3355886A1 (en) * 2015-08-28 2018-08-08 Novartis AG Pharmaceutical combination comprising the pi3k inhibitor alpelisib and the b-raf inhibitor dabrafenib; the use of such combination in the treatment or prevention of cancer
JP2018526375A (ja) * 2015-08-28 2018-09-13 ノバルティス アーゲー 組み合わせ療法
WO2017066664A1 (en) * 2015-10-16 2017-04-20 Millennium Pharmaceuticals, Inc. Combination therapy including a raf inhibitor for the treatment of colorectal cancer
MA45187A (fr) 2016-06-03 2019-04-10 Zhu Alexander Cao Combinaisons pharmaceutiques
CA3037456A1 (en) 2016-09-19 2018-03-22 Novartis Ag Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
TWI798218B (zh) 2017-05-02 2023-04-11 瑞士商諾華公司 組合療法
AU2018311523A1 (en) * 2017-08-03 2020-01-16 Novartis Ag Therapeutic combination of a third-generation EGFR tyrosine kinase inhibitor and a Raf inhibitor
PT3860998T (pt) 2018-10-05 2024-04-02 Annapurna Bio Inc Compostos e composições para o tratamento de condições associadas à atividade do recetor apj
TWI849043B (zh) * 2019-01-25 2024-07-21 英屬開曼群島商百濟神州有限公司 B-raf激酶二聚體抑制劑之穩定固體分散體、製備方法及其用途
WO2020164997A1 (en) * 2019-02-12 2020-08-20 Bayer Aktiengesellschaft Combination of pi3k-inhibitors
AU2020276695A1 (en) 2019-05-13 2021-12-23 Novartis Ag New crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as Raf inhibitors for the treatment of cancer
WO2023145530A1 (ja) * 2022-01-27 2023-08-03 国立大学法人東北大学 癌治療剤
WO2023230554A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
WO2024073364A1 (en) * 2022-09-26 2024-04-04 Beigene, Ltd. Combinations of a b-raf inhibitor, and an anti-egfr antibody for the treatment of cancer
WO2025003956A1 (en) 2023-06-30 2025-01-02 Pfizer Inc. High drug loading formulations of encorafenib

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
CA2683641C (en) 2007-04-10 2016-08-16 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
AU2010289794B2 (en) * 2009-08-24 2014-10-02 Genentech, Inc. Determining sensitivity of cells to B-Raf inhibitor treatment by detecting Kras mutation and RTK expression levels
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
CN102665720A (zh) * 2009-10-12 2012-09-12 葛兰素史密斯克莱有限责任公司 组合
US20120045433A1 (en) 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
US20130209461A1 (en) * 2010-11-08 2013-08-15 Novartis Ag Use of 2-carboxamide cycloamino urea derivatives in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members
EP2776413A1 (en) 2011-11-10 2014-09-17 Memorial Sloan-Kettering Cancer Center TREATMENT OF OVARIAN CANCER WITH 2-AMINO-4H-NAPHTHO[1,2-b]PYRAN-3-CARBONITRILES
CN108542906A (zh) * 2011-11-11 2018-09-18 诺华股份有限公司 治疗增生性疾病的方法
WO2014025688A1 (en) * 2012-08-07 2014-02-13 Novartis Ag Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor

Also Published As

Publication number Publication date
TWI607754B (zh) 2017-12-11
BR112015002384A8 (pt) 2023-01-31
CN104519887A (zh) 2015-04-15
MA37829A1 (fr) 2017-01-31
IL236934B (en) 2018-11-29
TR201904980T4 (tr) 2019-05-21
PT2882440T (pt) 2019-04-23
CY1122143T1 (el) 2020-11-25
PH12015500246B1 (en) 2015-03-30
PL2882440T3 (pl) 2019-07-31
JP6974669B2 (ja) 2021-12-01
JP2020019780A (ja) 2020-02-06
JP6342396B2 (ja) 2018-06-13
TW201410247A (zh) 2014-03-16
HK1204976A1 (en) 2015-12-11
PH12015500246A1 (en) 2015-03-30
US20150265616A1 (en) 2015-09-24
MX2015001732A (es) 2015-06-03
CA2879548C (en) 2020-07-21
PE20191655A1 (es) 2019-11-07
KR102112885B1 (ko) 2020-05-19
JP2015524472A (ja) 2015-08-24
AR092045A1 (es) 2015-03-18
AU2013299841A1 (en) 2015-02-12
EP2882440A1 (en) 2015-06-17
HUE042877T2 (hu) 2019-07-29
UA115786C2 (uk) 2017-12-26
CO7200273A2 (es) 2015-02-27
RS58734B1 (sr) 2019-06-28
AU2013299841B8 (en) 2017-01-05
IN2015DN00450A (OSRAM) 2015-06-26
JOP20130236B1 (ar) 2021-08-17
BR112015002384A2 (pt) 2017-07-04
HK1211831A1 (zh) 2016-06-03
HRP20190537T1 (hr) 2019-06-28
DK2882440T3 (da) 2019-05-06
EP2882440B1 (en) 2019-02-27
MX359403B (es) 2018-09-26
TN2015000027A1 (en) 2016-06-29
MY176031A (en) 2020-07-22
AU2013299841A8 (en) 2017-01-05
SG11201500321YA (en) 2015-04-29
AU2013299841B2 (en) 2016-11-24
CN104519887B (zh) 2017-06-27
JP2018109022A (ja) 2018-07-12
ES2717911T3 (es) 2019-06-26
WO2014025688A1 (en) 2014-02-13
KR20150040905A (ko) 2015-04-15
CA2879548A1 (en) 2014-02-13
EP3574904A1 (en) 2019-12-04
ECSP15008695A (es) 2019-03-29
LT2882440T (lt) 2019-04-25
SI2882440T1 (sl) 2019-05-31
CL2015000294A1 (es) 2015-05-08
PE20150673A1 (es) 2015-05-20
JP6595024B2 (ja) 2019-10-23
EA028420B1 (ru) 2017-11-30
NZ703940A (en) 2018-04-27
US9474754B2 (en) 2016-10-25
EA201590332A1 (ru) 2015-06-30

Similar Documents

Publication Publication Date Title
GT201500025A (es) Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa
CY1124311T1 (el) Παρεμποδιστες dna-pk
CL2015002807A1 (es) Terapia de combinación
AR091876A1 (es) Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
MX2016004580A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
EA201500314A1 (ru) Лекарственные формы энзалутамида
MX2016004030A (es) Inhibidores sustituidos de nicotinamida de btk y su preparacion y uso en el tratamiento del cancer, inflamacion y enfermedad autoinmune.
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
AR089993A1 (es) Macrociclos peptidomimeticos
MX2017005861A (es) Metodos para el control transcripcional objetivo en regiones del super mejorador.
MX2014016014A (es) Metodos para determinar eficacia de farmacos usando proteinas asociadas a cereblon.
EA201591616A1 (ru) Трифторметил-замещенные аннелированные пиримидины и их применение
EA201490546A1 (ru) Замещенные аннелированные пиримидины и их применение
GT201400162A (es) Composición y método para el diagnóstico y el tratamiento de las enfermedades asociadas a la degeneración de las neuritas
MX366317B (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
MX2015014438A (es) Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
CL2018003421A1 (es) Combinaciones farmacéuticas.
MX2015009045A (es) Composiciones y metodos para tratar el dolor severo.
CL2016000436A1 (es) Método para el tratamiento de la enfermedad fibrótica
MX2018005825A (es) Celulas inmunes modificadas y usos de las mismas.
UA114001C2 (xx) Оксазолідин-2-он-піримідинові похідні
CO7151543A2 (es) Combinaciones terapéuticas y métodos para tratar el melanoma
MX2015007719A (es) Terapia dirigida del receptor del factor de crecimiento epidermico (egfr) de trastornos neurologicos y dolor.
EA201500232A1 (ru) Три(гетеро)арилпиразолы и их применение
MX2015001695A (es) Regimenes de tratamiento.